• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Nucl Med Mol Imaging . Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell

tetano

Editor, Senior Moderator
Eur J Nucl Med Mol Imaging


. 2021 Jan 4.
doi: 10.1007/s00259-020-05154-6. Online ahead of print.
Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell


Maxime Niesen[SUP] 1 2 [/SUP], Nicola Trotta[SUP] 3 4 [/SUP], Antoine Noel[SUP] 5 [/SUP], Tim Coolen[SUP] 3 6 [/SUP], Georges Fayad[SUP] 5 [/SUP], Gil Leurkin-Sterk[SUP] 3 4 [/SUP], Isabelle Delpierre[SUP] 6 [/SUP], Sophie Henrard[SUP] 3 7 [/SUP], Niloufar Sadeghi[SUP] 6 [/SUP], Jean-Christophe Goffard[SUP] 7 [/SUP], Serge Goldman[SUP] 3 4 [/SUP], Xavier De Ti?ge[SUP] 3 4 [/SUP]



Affiliations

Abstract

Objectives: Sudden loss of smell is a very common symptom of coronavirus disease 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia in patients with COVID-19.
Methods: Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in 12 patients (2 males, 10 females, mean age: 42.6 years, age range: 23-60 years) with sudden dysosmia and positive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analyzed using a voxel-based approach and compared with that of a group of healthy subjects.
Results: Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Decrease or increase in glucose metabolism abnormalities was observed (p < .001 uncorrected, k ≥ 50 voxels) in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism by the severity and the duration of COVID-19-related dysosmia was disclosed using correlation analyses.
Conclusions: This PET-MR study suggests that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness. Loss of smell is associated with subtle cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganization secondary to the lack of olfactory stimulation.

Keywords: COVID-19; FDG-PET; MRI; Smell loss.
 
Back
Top Bottom